aTyr Pharma (471) Ratios
aTyr Pharma Ratios
DE:471's free cash flow for Q2 2026 was $-9.42M. For the 2026 fiscal year, DE:471's free cash flow was decreased by $-73.00K and operating cash flow was $-9.35M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.30 | 5.48 | 6.27 | 5.83 | 18.89 |
| Quick Ratio | 5.30 | 5.48 | 6.27 | 5.83 | 18.89 |
| Cash Ratio | 0.71 | 0.74 | 1.37 | 0.72 | 0.39 |
| Solvency Ratio | -2.70 | -2.31 | -1.58 | -1.78 | -5.06 |
| Operating Cash Flow Ratio | -4.09 | -4.62 | -2.02 | -3.02 | -5.50 |
| Short-Term Operating Cash Flow Coverage | -42.28 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 53.36M | $ 54.96M | $ 72.81M | $ 56.37M | $ 107.16M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.14 | 0.13 | 0.12 | 0.01 |
| Debt-to-Equity Ratio | 0.18 | 0.19 | 0.17 | 0.16 | 0.01 |
| Debt-to-Capital Ratio | 0.15 | 0.16 | 0.14 | 0.14 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | 1.38 | 1.33 | 1.34 | 1.06 |
| Debt Service Coverage Ratio | -49.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 5.18 | 0.18 | 0.28 | 0.41 | 0.07 |
| Net Debt to EBITDA | -0.02 | -0.04 | 0.14 | -0.03 | 0.03 |
| Profitability Margins | |||||
| Gross Profit Margin | -717.37% | 100.00% | 100.00% | 83.68% | 0.00% |
| EBIT Margin | -39009.47% | -27243.40% | -15557.79% | -446.79% | 0.00% |
| EBITDA Margin | -38192.11% | -26588.09% | -14781.30% | -430.47% | 0.00% |
| Operating Profit Margin | -40856.32% | -28899.57% | -15557.79% | -446.79% | 0.00% |
| Pretax Profit Margin | -39009.47% | -27243.40% | -14276.77% | -436.58% | 0.00% |
| Net Profit Margin | -39009.47% | -27243.83% | -14274.50% | -436.53% | 0.00% |
| Continuous Operations Profit Margin | -39009.47% | -27243.40% | -14276.77% | -436.58% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 99.98% | 99.99% | 99.97% |
| EBT Per EBIT | 95.48% | 94.27% | 91.77% | 97.71% | 99.30% |
| Return on Assets (ROA) | -78.71% | -66.12% | -41.76% | -47.33% | -29.23% |
| Return on Equity (ROE) | -109.84% | -91.44% | -55.58% | -63.44% | -30.89% |
| Return on Capital Employed (ROCE) | -98.24% | -82.96% | -52.69% | -56.64% | -31.06% |
| Return on Invested Capital (ROIC) | -96.45% | -81.71% | -52.02% | -56.03% | -30.78% |
| Return on Tangible Assets | -78.71% | -66.12% | -41.76% | -47.33% | -29.23% |
| Earnings Yield | -101.80% | -23.82% | -54.33% | -92.21% | -102.30% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.22 | 0.14 | 0.14 | 0.88 | 0.00 |
| Payables Turnover | 0.40 | 0.00 | 0.00 | 0.55 | 1.26 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.02 | 0.02 | 0.03 | 0.90 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.11 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 |
| Cash Conversion Cycle | 762.58 | 2696.34 | 2518.81 | -255.03 | -288.59 |
| Days of Sales Outstanding | 1677.08 | 2696.34 | 2518.81 | 413.81 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 914.50 | 0.00 | 0.00 | 668.84 | 288.59 |
| Operating Cycle | 1677.08 | 2696.34 | 2518.81 | 413.81 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -26.66 | -0.93 | -0.62 | -1.47 | -1.73 |
| Free Cash Flow Per Share | -26.70 | -0.93 | -0.70 | -1.53 | -1.74 |
| Dividend Paid and CapEx Coverage Ratio | -805.01 | -1063.37 | -7.88 | -25.52 | -172.27 |
| Capital Expenditure Coverage Ratio | -805.01 | -1063.37 | -7.88 | -25.52 | -172.27 |
| Operating Cash Flow Coverage Ratio | -5.15 | -5.20 | -2.20 | -3.63 | -24.00 |
| Operating Cash Flow to Sales Ratio | -326.24 | -294.12 | -94.11 | -4.03 | 0.00 |
| Free Cash Flow Yield | -85.24% | -25.74% | -40.37% | -88.53% | -100.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.98 | -4.21 | -1.84 | -1.08 | -0.98 |
| Price-to-Sales (P/S) Ratio | 383.20 | 1143.94 | 262.72 | 4.73 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.08 | 3.84 | 1.02 | 0.69 | 0.30 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.17 | -3.89 | -2.48 | -1.13 | -0.99 |
| Price-to-Operating Cash Flow Ratio | -1.17 | -3.89 | -2.79 | -1.17 | -1.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.14 | 0.49 | 0.04 | 0.11 | 0.00 |
| Enterprise Value Multiple | -1.02 | -4.34 | -1.63 | -1.13 | -0.99 |
| Enterprise Value | 74.10M | 271.05M | 85.29M | 50.72M | 32.05M |
| EV to EBITDA | -1.02 | -4.34 | -1.63 | -1.13 | -0.99 |
| EV to Sales | 389.99 | 1153.42 | 241.62 | 4.88 | 0.00 |
| EV to Free Cash Flow | -1.19 | -3.92 | -2.28 | -1.17 | -0.96 |
| EV to Operating Cash Flow | -1.20 | -3.92 | -2.57 | -1.21 | -0.97 |
| Tangible Book Value Per Share | 28.95 | 0.94 | 1.69 | 2.51 | 5.72 |
| Shareholders’ Equity Per Share | 29.03 | 0.94 | 1.69 | 2.51 | 5.73 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.08 | 0.00 | 0.01 | 0.37 | 0.00 |
| Net Income Per Share | -31.88 | -0.86 | -0.94 | -1.60 | -1.77 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.92 | 0.98 | 1.00 |
| Research & Development to Revenue | 316.94 | 231.37 | 119.81 | 4.12 | 0.00 |
| SG&A to Revenue | 92.62 | 58.63 | 36.77 | 1.35 | 0.00 |
| Stock-Based Compensation to Revenue | 26.30 | 12.72 | 7.37 | 0.21 | 0.00 |
| Income Quality | 0.84 | 1.08 | 0.66 | 0.92 | 0.98 |
Currency in USD
